OPTOMED OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.11 EUR | +3.01% |
|
-0.84% | +10.63% |
| Feb. 15 | Transcript : Optomed Oyj, 2023 Earnings Call, Feb 15, 2024 | |
| Feb. 15 | Optomed Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 16.79M 18.02M | Sales 2025 * | 25.35M 27.21M | Capitalization | 70.93M 76.12M |
|---|---|---|---|---|---|
| Net income 2024 * | -3M -3.22M | Net income 2025 * | -2M -2.15M | EV / Sales 2024 * | 4.28 x |
| Net Debt 2024 * | 965K 1.04M | Net Debt 2025 * | 4.58M 4.91M | EV / Sales 2025 * | 2.98 x |
| P/E ratio 2024 * |
-18.1
x | P/E ratio 2025 * |
-25.7
x | Employees | 114 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Optomed Oyj
More news
| 1 day | +0.88% | ||
| 1 week | -2.90% | ||
| Current month | +1.90% | ||
| 1 month | +1.13% | ||
| 3 months | +4.27% | ||
| 6 months | +57.53% | ||
| Current year | +8.34% |
1 week
3.96
4.21
1 month
3.924.67
Current year
3.264.67
1 year
2.314.67
3 years
2.0219.15
5 years
2.0219.15
10 years
2.0219.15
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 23-09-30 | |
| Director of Finance/CFO | 40 | 18-12-31 | |
Petri Huhtinen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 66 | 05-12-31 | |
| Director/Board Member | 72 | 18-12-31 | |
| Director/Board Member | 68 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.11 | +3.01% | 26 049 |
| 24-04-25 | 3.99 | -3.86% | 24,867 |
| 24-04-24 | 4.15 | -0.84% | 17,422 |
| 24-04-23 | 4.185 | 0.00% | 12,663 |
| 24-04-22 | 4.185 | +0.97% | 11,443 |
Delayed Quote Nasdaq Helsinki, April 26, 2024 at 06:58 am EDT
More quotes
Optomed Oyj is a Finland-based medical technology company and a producer of handheld fundus cameras globally. The Group's Parent Company, Optomed Oyj, is responsible for, among other things, the management of the Group as well as finance and accounting functions, human resources, legal affairs and corporate communication. The Group's business is managed through two reportable segments: Devices and Software. The Devices segment develops, commercializes and manufactures easy-to-use and affordable handheld fundus cameras. The Software segment develops and sells screening software for diabetic retinopathy and cancer screening for healthcare organizations. The Optomed Group consists of the parent company Optomed Oyj and four subsidiaries in Finland, China, the USA and Hong Kong.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.99
EUR
Average target price
5.8
EUR
Spread / Average Target
+45.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.34% | 75.98M | |
| +7.71% | 218B | |
| +6.25% | 182B | |
| +10.60% | 132B | |
| +26.73% | 108B | |
| -0.46% | 62.51B | |
| +15.42% | 52.98B | |
| -1.89% | 47.59B | |
| -1.91% | 39.96B | |
| +11.16% | 39.22B |
- Stock Market
- Equities
- OPTOMED Stock
